← Leaderboards
Li Ma
University Of Tx Md Anderson Can Ctr
$7,923,692
Attributed
$7,923,692
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,923,692 · 6
By mechanism
R01$7,036,425 · 4
R00$731,893 · 1
K99$155,374 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Guang Peng$3,599,803
- Heath Devin Skinner$8,539,031
- Boyi Gan$13,125,533
- Dihua Yu$18,443,603
- James Martin Reuben$2,326,772
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingNeoplastic CellTumorBreast Cancer CellCellsMalignant NeoplasmsMolecularMicrornasNeoplasm MetastasisOverexpressionBaseTranscription FactorBiological MarkersTherapeutic TargetProteinsIn VivoReportingDown-RegulationMalignant Breast NeoplasmInsightFutureE-CadherinMesenchymalPlay
Grant awards (24)
Study of a new driver and therapeutic vulnerability of bone metastasis$564,695
R01 · FY2025 · CA · contact PI
Targeting the LIFR-LCN2 pathway to improve liver cancer therapy$480,131
R01 · FY2025 · CA · contact PI
Targeting the LIFR-LCN2 pathway to improve liver cancer therapy$456,124
R01 · FY2024 · CA · contact PI
Targeting the LIFR-LCN2 pathway to improve liver cancer therapy$480,131
R01 · FY2023 · CA · contact PI
Non-coding RNA functions in tumor metastasis$352,800
R01 · FY2023 · CA · contact PI
Non-coding RNA functions in tumor metastasis$352,800
R01 · FY2022 · CA · contact PI
Non-coding RNA functions in tumor metastasis$360,000
R01 · FY2021 · CA · contact PI
Non-coding RNA functions in tumor metastasis$360,000
R01 · FY2020 · CA · contact PI
Non-coding RNA functions in tumor metastasis$360,000
R01 · FY2019 · CA · contact PI
Epithelial-mesenchymal transition regulators in radioresistance and DNA repair$332,000
R01 · FY2018 · CA · contact PI
Epithelial-mesenchymal transition regulators in radioresistance and DNA repair$332,000
R01 · FY2017 · CA · contact PI
Epithelial-mesenchymal transition regulators in radioresistance and DNA repair$332,000
R01 · FY2016 · CA · contact PI
Regulation of metastasis and epithelial-mesenchymal transition by microRNAs$327,850
R01 · FY2016 · CA · contact PI
Epithelial-mesenchymal transition regulators in radioresistance and DNA repair$332,000
R01 · FY2015 · CA · contact PI
Regulation of metastasis and epithelial-mesenchymal transition by microRNAs$327,850
R01 · FY2015 · CA · contact PI
Epithelial-mesenchymal transition regulators in radioresistance and DNA repair$332,000
R01 · FY2014 · CA · contact PI
Regulation of metastasis and epithelial-mesenchymal transition by microRNAs$318,015
R01 · FY2014 · CA · contact PI
Regulation of metastasis and epithelial-mesenchymal transition by microRNAs$308,179
R01 · FY2013 · CA · contact PI
Regulation of metastasis and epithelial-mesenchymal transition by microRNAs$327,850
R01 · FY2012 · CA · contact PI
Role of microRNAs in malignant progression$241,475
R00 · FY2012 · CA · contact PI
Role of microRNAs in malignant progression$241,475
R00 · FY2011 · CA · contact PI
Role of microRNAs in malignant progression$248,943
R00 · FY2010 · CA · contact PI
Role of microRNAs in malignant progression$44,637
K99 · FY2010 · CA · contact PI
Role of microRNAs in malignant progression$110,737
K99 · FY2009 · CA · contact PI